Valuation Metrics and Recent Changes
Fredun Pharmaceuticals currently trades at a price of ₹993.80, up 6.54% from the previous close of ₹932.78, touching a 52-week high of ₹999.00. The company’s price-to-earnings (P/E) ratio stands at 43.87, a figure that has nudged the valuation grade from attractive to fair as of 16 July 2026. This P/E is slightly above the peer average of 43.19, signalling that while the stock remains richly valued, it is no longer at a discount relative to its sector comparators.
The price-to-book value (P/BV) ratio is 5.90, which is elevated but consistent with the pharmaceutical industry’s premium multiples, reflecting investor confidence in the company’s asset utilisation and growth prospects. Other valuation multiples such as EV to EBIT (20.72) and EV to EBITDA (18.99) further corroborate the fair valuation stance, indicating that the enterprise value is priced to reflect solid earnings before interest and taxes, as well as cash flow generation.
Comparative Industry Analysis
When benchmarked against key peers, Fredun Pharmaceuticals occupies a middle ground in valuation. For instance, Bliss GVS Pharma and Kwality Pharma are classified as very expensive with P/E ratios of 41.69 and 42.93 respectively, but with significantly higher EV to EBITDA multiples of 32.31 and 25.75. Venus Remedies, rated expensive, trades at a lower P/E of 23.51 but with a more modest EV to EBITDA of 15.79. This positions Fredun as fairly valued relative to its sector, balancing growth expectations with current earnings quality.
Notably, Fredun’s PEG ratio of 0.74 suggests that the stock’s price growth is still reasonably aligned with earnings growth, a positive indicator compared to some peers with higher PEG ratios, such as Jagsonpal Pharma at 2.09, which may imply overvaluation relative to growth.
Crushing the market! This Small Cap from Aerospace & Defense just earned its spot in our Top 1% with impressive gains. Don't let this opportunity slip through your hands.
- - Recent Top 1% qualifier
- - Impressive market performance
- - Sector leader
Operational Efficiency and Returns
Fredun Pharmaceuticals demonstrates robust operational metrics, with a return on capital employed (ROCE) of 19.94% and return on equity (ROE) of 13.65%. These figures underscore efficient capital utilisation and profitability, supporting the company’s premium valuation multiples. The dividend yield remains minimal at 0.04%, indicating a growth-oriented strategy with earnings reinvested to fuel expansion rather than distributed as dividends.
Such strong returns on capital are particularly noteworthy for a micro-cap entity, suggesting that Fredun is effectively leveraging its resources to generate shareholder value despite its smaller market capitalisation.
Price Performance Versus Market Benchmarks
Fredun Pharmaceuticals has delivered exceptional price returns over multiple time horizons, significantly outperforming the Sensex. Year-to-date, the stock has surged 90.81%, while the Sensex has declined by 9.43%. Over the past year, Fredun’s return of 217.00% dwarfs the Sensex’s negative 6.59% performance. Even on a longer-term basis, the stock’s 10-year return of 11,946.06% far exceeds the Sensex’s 177.29% gain, highlighting its status as a market outperformer within the Pharmaceuticals & Biotechnology sector.
Such extraordinary returns have contributed to the upward pressure on valuation multiples, prompting a reassessment of the stock’s price attractiveness from attractive to fair.
Micro-Cap Status and Market Sentiment
Fredun’s micro-cap classification reflects its relatively modest market capitalisation compared to larger pharmaceutical companies. This status often entails higher volatility and greater sensitivity to market sentiment, which is evident in the stock’s 6.54% day change and intraday price range between ₹945.00 and ₹999.00.
Investors should weigh the company’s strong growth trajectory and operational efficiency against the inherent risks associated with smaller capitalisation stocks, including liquidity constraints and sector-specific regulatory challenges.
Considering Fredun Pharmaceuticals Ltd? Wait! SwitchER has found potentially better options in Pharmaceuticals & Biotechnology and beyond. Compare this micro-cap with top-rated alternatives now!
- - Better options discovered
- - Pharmaceuticals & Biotechnology + beyond scope
- - Top-rated alternatives ready
Outlook and Investment Considerations
Fredun Pharmaceuticals’ transition from an attractive to a fair valuation grade signals a maturing market view that recognises both the company’s impressive growth and the premium now embedded in its share price. The current Mojo Score of 68.0 and a Hold grade, downgraded from Buy on 16 July 2026, reflect a cautious stance amid elevated multiples.
Investors should consider the stock’s strong fundamentals, including high ROCE and ROE, alongside its stretched valuation metrics. The PEG ratio below 1.0 indicates that earnings growth still supports the price, but the high P/E and P/BV ratios suggest limited margin for multiple expansion.
Given the stock’s micro-cap status, potential volatility remains a factor, and investors may wish to monitor sector developments and peer valuations closely. The company’s ability to sustain operational efficiency and deliver consistent earnings growth will be critical to justifying its current valuation.
In summary, Fredun Pharmaceuticals offers a compelling growth story tempered by a fair valuation rating, making it a stock for investors who favour quality growth with an awareness of valuation discipline.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
